Moderna (NASDAQ:MRNA) Given Overweight Rating at Piper Sandler

Piper Sandler reiterated their overweight rating on shares of Moderna (NASDAQ:MRNA) in a research note issued to investors on Thursday, Benzinga reports. Piper Sandler currently has a $214.00 target price on the stock.

Several other research analysts also recently weighed in on the stock. Jefferies Financial Group reissued a buy rating and issued a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. Evercore ISI reissued an in-line rating and issued a $120.00 price objective on shares of Moderna in a research report on Thursday. Needham & Company LLC restated a hold rating on shares of Moderna in a research report on Monday, June 3rd. William Blair reiterated a market perform rating on shares of Moderna in a report on Monday, April 1st. Finally, UBS Group raised their price objective on Moderna from $143.00 to $151.00 and gave the stock a buy rating in a report on Tuesday, May 7th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Moderna currently has an average rating of Hold and a consensus target price of $134.02.

Moderna Stock Down 2.0 %

Shares of NASDAQ MRNA opened at $118.75 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. The firm’s 50-day moving average is $134.13 and its two-hundred day moving average is $112.19. Moderna has a 12-month low of $62.55 and a 12-month high of $170.47. The company has a market capitalization of $45.51 billion, a PE ratio of -7.58 and a beta of 1.54.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. The firm had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. Moderna’s revenue was down 91.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.19 EPS. Equities analysts anticipate that Moderna will post -7.46 EPS for the current fiscal year.

Insider Activity at Moderna

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $101.68, for a total value of $1,525,200.00. Following the completion of the transaction, the director now owns 2,086,931 shares in the company, valued at approximately $212,199,144.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $101.68, for a total transaction of $1,525,200.00. Following the completion of the sale, the director now directly owns 2,086,931 shares in the company, valued at $212,199,144.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 705 shares of the business’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $101.93, for a total value of $71,860.65. Following the completion of the transaction, the chief financial officer now owns 5,048 shares in the company, valued at approximately $514,542.64. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 411,255 shares of company stock worth $56,118,931. 15.70% of the stock is currently owned by company insiders.

Institutional Trading of Moderna

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Ogorek Anthony Joseph NY ADV bought a new position in Moderna during the 4th quarter valued at $27,000. Arlington Trust Co LLC lifted its position in shares of Moderna by 4,833.3% during the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after purchasing an additional 290 shares during the last quarter. Cedar Wealth Management LLC grew its stake in Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares in the last quarter. Westside Investment Management Inc. acquired a new position in Moderna in the first quarter worth about $32,000. Finally, Rise Advisors LLC increased its holdings in Moderna by 953.3% in the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after buying an additional 286 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.